Stock Track | AxoGen Stock Soars 7.85% Pre-Market on Strong Q3 Earnings Beat

Stock Track

Oct 29, 2025

AxoGen Inc. (NASDAQ: AXGN) saw its stock price surge 7.85% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results. The company, which specializes in peripheral nerve repair solutions, reported earnings that significantly exceeded analyst expectations.

The medical technology firm announced Q3 revenue of $60.1 million, handily beating the IBES estimate of $56.8 million. This strong top-line performance was accompanied by a healthy gross margin of 76.6%, indicating efficient operations and pricing power. AxoGen also reported adjusted EBITDA of $9.2 million and adjusted net income of $6.1 million for the quarter, demonstrating improved profitability.

Investors were particularly encouraged by AxoGen's bottom-line performance, with the company posting a net income of $700,000. This return to profitability, coupled with the revenue beat, appears to be driving the substantial pre-market stock price increase. The results suggest that AxoGen's innovative nerve repair technologies are gaining traction in the medical community, potentially setting the stage for continued growth in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1145122090"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1145122090\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1145122090?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145122090","market":"us","top_or_hot":-1,"title":"Stock Track | AxoGen Stock Soars 7.85% Pre-Market on Strong Q3 Earnings Beat","media":"Stock Track","content":"<p>AxoGen Inc. (NASDAQ: AXGN) saw its stock price surge 7.85% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results. The company, which specializes in peripheral nerve repair solutions, reported earnings that significantly exceeded analyst expectations.</p>\n\n<p>The medical technology firm announced Q3 revenue of $60.1 million, handily beating the IBES estimate of $56.8 million. This strong top-line performance was accompanied by a healthy gross margin of 76.6%, indicating efficient operations and pricing power. AxoGen also reported adjusted EBITDA of $9.2 million and adjusted net income of $6.1 million for the quarter, demonstrating improved profitability.</p>\n\n<p>Investors were particularly encouraged by AxoGen's bottom-line performance, with the company posting a net income of $700,000. This return to profitability, coupled with the revenue beat, appears to be driving the substantial pre-market stock price increase. The results suggest that AxoGen's innovative nerve repair technologies are gaining traction in the medical community, potentially setting the stage for continued growth in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AxoGen Stock Soars 7.85% Pre-Market on Strong Q3 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AxoGen Stock Soars 7.85% Pre-Market on Strong Q3 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-29 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AxoGen Inc. (NASDAQ: AXGN) saw its stock price surge 7.85% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results. The company, which specializes in peripheral nerve repair solutions, reported earnings that significantly exceeded analyst expectations.</p>\n\n<p>The medical technology firm announced Q3 revenue of $60.1 million, handily beating the IBES estimate of $56.8 million. This strong top-line performance was accompanied by a healthy gross margin of 76.6%, indicating efficient operations and pricing power. AxoGen also reported adjusted EBITDA of $9.2 million and adjusted net income of $6.1 million for the quarter, demonstrating improved profitability.</p>\n\n<p>Investors were particularly encouraged by AxoGen's bottom-line performance, with the company posting a net income of $700,000. This return to profitability, coupled with the revenue beat, appears to be driving the substantial pre-market stock price increase. The results suggest that AxoGen's innovative nerve repair technologies are gaining traction in the medical community, potentially setting the stage for continued growth in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AXGN","symbol_name":"AxoGen Inc.","start_time":0,"source_url":"","article_id":"1145122090","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145122090","pubTimestamp":1761735741,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AxoGen Inc. (NASDAQ: AXGN) saw its stock price surge 7.85% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results. The company, which specializes in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AXGN":"AxoGen Inc."},"translate_title":"股票追踪|第三季度盈利强劲，AxoGen股价盘前飙升7.85%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXGN":1},"content_text":"AxoGen Inc. (NASDAQ: AXGN) saw its stock price surge 7.85% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results. The company, which specializes in peripheral nerve repair solutions, reported earnings that significantly exceeded analyst expectations.\nThe medical technology firm announced Q3 revenue of $60.1 million, handily beating the IBES estimate of $56.8 million. This strong top-line performance was accompanied by a healthy gross margin of 76.6%, indicating efficient operations and pricing power. AxoGen also reported adjusted EBITDA of $9.2 million and adjusted net income of $6.1 million for the quarter, demonstrating improved profitability.\nInvestors were particularly encouraged by AxoGen's bottom-line performance, with the company posting a net income of $700,000. This return to profitability, coupled with the revenue beat, appears to be driving the substantial pre-market stock price increase. The results suggest that AxoGen's innovative nerve repair technologies are gaining traction in the medical community, potentially setting the stage for continued growth in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}